337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials

Hassanieh, S., Domingo, E., Blake, A. et al. (16 more authors) (2022) 337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials. In: Annals of Oncology. ESMO Congress 2022, 09-13 Sep 2022, Paris, France. Elsevier , S691.

Metadata

Item Type: Proceedings Paper
Authors/Creators:
Dates:
  • Published: 13 September 2022
  • Published (online): 13 September 2022
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Medical Research (LIMR) > Division of Oncology
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Medical Research (LIMR) > Division of Pathology and Data Analytics
Funding Information:
Funder
Grant number
Cancer Research UK Supplier No: 138573
RCS REF 08-0843 SUBCONTR
Cancer Research UK Supplier No: 138573
C6003/A7367
Cancer Research UK Supplier No: 138573
C7852/A19772
Cancer Research UK Supplier No: 138573
C6003/A3830
MRC (Medical Research Council)
NOT GIVEN
Leeds Hospitals Charity
1T01-A321
Leeds Teaching Hospitals Charitable Foundation
4616
Depositing User: Symplectic Publications
Date Deposited: 17 Jul 2023 08:14
Last Modified: 17 Jul 2023 08:14
Status: Published
Publisher: Elsevier
Identification Number: 10.1016/j.annonc.2022.07.475
Related URLs:
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics